CY1105528T1 - Παρασκευaσματα σταθεροποιημeνα για μακρo διaστημα - Google Patents

Παρασκευaσματα σταθεροποιημeνα για μακρo διaστημα

Info

Publication number
CY1105528T1
CY1105528T1 CY20061101080T CY061101080T CY1105528T1 CY 1105528 T1 CY1105528 T1 CY 1105528T1 CY 20061101080 T CY20061101080 T CY 20061101080T CY 061101080 T CY061101080 T CY 061101080T CY 1105528 T1 CY1105528 T1 CY 1105528T1
Authority
CY
Cyprus
Prior art keywords
csf
long
residual
ratio
test
Prior art date
Application number
CY20061101080T
Other languages
English (en)
Inventor
Yasushi Sato
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of CY1105528T1 publication Critical patent/CY1105528T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Fodder In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Amplifiers (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Σταθερά παρασκευάσματα G-CSF που διαθέτουν υπολειμματικό λόγο G-CSF 90% ή περισσότερο έπειτα από μακροχρόνια δοκιμή αποθήκευση στους 25°C για 3μήνες˙ υπολειμματικό λόγο G-CSF 90% ή περισσότερο έπειτα από μακροχρόνια δοκιμή αποθήκευση στους 40°C για 2 μήνες˙ υπολειμματικό λόγο G-CSF 90% ή περισσότερο έπειτα από μακροχρόνια δοκιμή αποθήκευση στους 50°C για 1 μήνα˙ ή υπολειμματικό λόγο G-CSF 90% ή περισσότερο έπειτα από επιταχυνόμενη δοκιμή στους 50°C για 1 μήνα˙ ή υπολειμματικό λόγο G-CSF 90% ή περισσότερο έπειτα από επιταχυνόμενη δοκιμή στους 60°C για δύο εβδομάδες˙ και λόγο σχηματισμού παραγώγου met-οξειδωμένης G-CSF 1% ή λιγότερο, έπειτα από επιταχυνόμενη δοκιμή στους 50°C για 1 μήνα ή έπειτα από επιταχυνόμενη δοκιμή στους 60°C για 2 εβδομάδες. Μέθοδος αναστολής του σχηματισμού του met-οξειδωμένου παραγώγου μιας φυσιολογικώς δραστικής πρωτεΐνης, με υπολείμματα μεθειονίνης, χαρακτηριζόμενη από την προσθήκη μεθειονίνης σε σύνθεση που περιέχει αυτήν την πρωτεΐνη
CY20061101080T 1999-03-01 2006-08-02 Παρασκευaσματα σταθεροποιημeνα για μακρo διaστημα CY1105528T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11052314A JP2000247903A (ja) 1999-03-01 1999-03-01 長期安定化製剤
PCT/JP2000/001160 WO2000051629A1 (fr) 1999-03-01 2000-02-29 Preparations stabilisees a longue conservation

Publications (1)

Publication Number Publication Date
CY1105528T1 true CY1105528T1 (el) 2010-07-28

Family

ID=12911333

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101080T CY1105528T1 (el) 1999-03-01 2006-08-02 Παρασκευaσματα σταθεροποιημeνα για μακρo διaστημα

Country Status (16)

Country Link
US (1) US6908610B1 (el)
EP (2) EP1197221B1 (el)
JP (2) JP2000247903A (el)
KR (2) KR100731559B1 (el)
CN (3) CN101537173A (el)
AT (1) ATE326233T1 (el)
AU (1) AU772604B2 (el)
CA (1) CA2381229C (el)
CY (1) CY1105528T1 (el)
DE (1) DE60028037T2 (el)
DK (1) DK1197221T3 (el)
ES (1) ES2263450T3 (el)
HK (3) HK1045652A1 (el)
PT (1) PT1197221E (el)
TW (1) TWI232749B (el)
WO (1) WO2000051629A1 (el)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60034149T2 (de) * 1999-12-24 2007-12-13 Otsuka Pharmaceutical Co., Ltd. Hydrophobe aminosäuren enthaltende trockene zusammensetzung
JP4683810B2 (ja) 2000-02-29 2011-05-18 中外製薬株式会社 長期安定化製剤
CN1309416C (zh) * 2000-05-15 2007-04-11 霍夫曼-拉罗奇有限公司 新的药物组合物
WO2002017957A1 (fr) * 2000-09-01 2002-03-07 Chugai Seiyaku Kabushiki Kaisha Preparations de solutions stabilisees sur une longue periode de temps
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
EP1479393B1 (en) * 2002-02-28 2010-08-18 Nipro Corporation Stabilized albumin preparations
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
WO2004019966A1 (ja) * 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液製剤の安定化方法
US8765124B2 (en) 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
MXPA05009914A (es) * 2003-03-18 2006-01-09 Novo Nordisk Healthcare Ag Composiciones farmaceuticas acuosas, liquidas de polipeptidos del factor vii.
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
PL2335725T3 (pl) * 2003-04-04 2017-04-28 Genentech, Inc. Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
MXPA05012476A (es) * 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
AU2004288854B2 (en) * 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
KR20060109950A (ko) * 2003-12-19 2006-10-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
JP2005310840A (ja) 2004-04-16 2005-11-04 Toshiba Corp 磁気ランダムアクセスメモリ
US20060293243A1 (en) * 2005-06-17 2006-12-28 Navneet Puri Stable, buffered, pharmaceutical compositions including motilin-like peptides
US7534753B2 (en) * 2006-01-12 2009-05-19 Air Products And Chemicals, Inc. pH buffered aqueous cleaning composition and method for removing photoresist residue
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
EP1997505A4 (en) * 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd PREPARATION OF ERYTHROPOIETIN SOLUTION
CA2679551C (en) 2007-04-05 2014-10-21 Sandoz Ag Stable aqueous g-csf formulations
US20080286471A1 (en) * 2007-05-18 2008-11-20 Doubleday Marc D Protective gel for an electrical connection
EP2170268A2 (en) * 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
US8617568B2 (en) 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
BRPI0907371A2 (pt) 2008-01-09 2015-11-24 Sanofi Aventis Deutschland derivados de insulina com um perfil de tempo-ação muito retardado
KR20110076918A (ko) * 2008-09-10 2011-07-06 제넨테크, 인크. 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
RS59743B1 (sr) * 2010-01-15 2020-02-28 Kirin Amgen Inc Formulacija antitela protiv il-17ra i terapeutski režimi za lečenje psorijaze
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
KR101903931B1 (ko) 2010-03-01 2018-10-02 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN102028661B (zh) * 2010-12-31 2012-05-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2827951A4 (en) * 2012-03-21 2016-07-13 Futurestem Llc COMBINATION THERAPY TO IMPROVE THE HEALING OF JOINTS, TIGHTS AND TAPES
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
RU2019137020A (ru) * 2013-03-13 2021-01-14 Дженентек, Инк. Составы со сниженным окислением
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
JP6389236B2 (ja) * 2013-03-13 2018-09-12 ジェネンテック， インコーポレイテッド 酸化還元製剤
JP6461005B2 (ja) * 2013-11-21 2019-01-30 協和メデックス株式会社 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法
AU2015205620A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin aspart
RU2016132386A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
CN104524553B (zh) * 2014-12-12 2015-07-29 薛传校 一种长效促***注射液
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
CN109627300B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin溶液稳定剂开发及应用
WO2021195877A1 (en) * 2020-03-30 2021-10-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of human parathyroid hormone (pth) and methods for producing same
WO2023066988A1 (en) 2021-10-19 2023-04-27 Sandoz Ag Glass container with low aluminum content and gas overlay to prevent oxidation of sensitive therapeutic agents
CN115624187B (zh) * 2022-12-08 2023-04-04 北京第一生物科技开发有限公司 牛脾肽粉在改善睡眠中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
JP2577744B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP2974722B2 (ja) * 1990-04-03 1999-11-10 帝国臓器製薬株式会社 カルシトニン注射液
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
JPH05331071A (ja) * 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
CZ20021186A3 (cs) * 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid

Also Published As

Publication number Publication date
KR100731559B1 (ko) 2007-06-22
CA2381229C (en) 2010-10-26
EP1197221B1 (en) 2006-05-17
ES2263450T3 (es) 2006-12-16
JP4607336B2 (ja) 2011-01-05
EP1700605A3 (en) 2007-06-13
KR100656125B1 (ko) 2006-12-12
HK1045652A1 (zh) 2002-12-06
CN1879875B (zh) 2010-08-25
CN101537173A (zh) 2009-09-23
EP1197221A4 (en) 2003-01-29
DK1197221T3 (da) 2006-11-13
ATE326233T1 (de) 2006-06-15
HK1046239A1 (en) 2003-01-03
JP2000247903A (ja) 2000-09-12
AU2695400A (en) 2000-09-21
DE60028037D1 (de) 2006-06-22
DE60028037T2 (de) 2006-12-21
KR20010102469A (ko) 2001-11-15
HK1098963A1 (en) 2007-08-03
EP1700605A2 (en) 2006-09-13
US6908610B1 (en) 2005-06-21
TWI232749B (en) 2005-05-21
HK1046239B (zh) 2006-08-18
WO2000051629A1 (fr) 2000-09-08
CN1342087A (zh) 2002-03-27
PT1197221E (pt) 2006-08-31
KR20050099637A (ko) 2005-10-14
EP1700605B1 (en) 2014-04-30
CN1879875A (zh) 2006-12-20
CA2381229A1 (en) 2000-09-08
EP1197221A1 (en) 2002-04-17
AU772604B2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
CY1105528T1 (el) Παρασκευaσματα σταθεροποιημeνα για μακρo διaστημα
YU149791A (sh) Mometason, furoat monohidrat i postupak za njegovo dobijanje
DE69620877T2 (de) Arzneimittelformulierungen für il-12
PT758248E (pt) Formulacoes para o factor ix
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
IT7947847A0 (it) Derivati dell'imidazolo relativo procedimento di produzione e composizioni farmaceutiche che li contengono come ingrediente attivo
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
PT1311285E (pt) Composicao farmaceutica liquida contendo um derivado de eritropoietina
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
ES2062310T3 (es) Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
BR0012429A (pt) Fórmulações para il-11
ATE233543T1 (de) Kreatin, karnitin und/oder brenztraubensäure enthaltende kosmetische zusammensetzungen
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
BR9814523A (pt) "composição farmacêutica contendo cloridrato de bupropion e um estabilizador de ácido inorgânico"
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη
IL63315A (en) Acid stabilized pharmaceutical compositions of thieno-pyridine derivatives
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
ES2149736T1 (es) Composiciones farmaceuticas conteniendo derivados de tienopiridina estables y libres de antioxidantes.
EA200400954A1 (ru) Фармацевтическая композиция, содержащая 2,2-дихлор-12-(4-хлорфенил)додекановую кислоту
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
ATE232724T1 (de) Inhibitor von stickstoffmonoxid (no) synthase zur verhütung von typ ii diabetes
IT9022371A0 (it) Derivati dell'1-arilsolfonil 2-pirrolidone, loro procedimento di preparazione e i nuovi intermedi cosi' ottenuti, il loro impiego come farmaci e le composizioni farmaceutiche che li contengono.
PT925785E (pt) Composicao farmaceutica estabilizada que contem dopamina ou dobutamina
IT1299623B1 (it) Composizione per uso cosmetico o farmaceutico a base di acido lipoico e acido piruvico